The Hackett Group® Recognizes Employ as a Top Performer in its Talent Acquisition Software Provider Matrix™ 2025
05. Februar 2025 07:00 ET
|
Employ Inc.
The Hackett Group® Recognizes Employ as a Top Performer in its Talent Acquisition Software Provider Matrix™ 2025
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
29. Januar 2025 08:00 ET
|
aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
BLOX Markets, Inc. and OptimX Markets Enter into Early-Stage Partnership
19. Dezember 2024 09:06 ET
|
BLOX Markets, Inc.; OptimX Markets
Joint Press Release NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- BLOX Markets, Inc. is excited to announce an early-stage partnership with OptimX Markets, an innovative liquidity management...
Employ Inc. Announces Promotion of Stephanie Manzelli to Chief Human Resources Officer
06. November 2024 07:00 ET
|
Employ Inc.
Employ Promotes Stephanie Manzelli to CHRO
Employ Inc. Appoints Joey Humke as Chief Revenue Officer
23. September 2024 07:00 ET
|
Employ Inc.
Employ Inc. Appoints Joey Humke as Chief Revenue Officer
Kula debuts the first complete hiring platform with purpose-built AI for recruiting
19. September 2024 10:00 ET
|
Kula
San Francisco, California, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The rise of AI has transformed the recruiting playbook. At least 62 percent of recruiters expressed optimism about AI’s impact on...
Employ Inc. Opens Center of Excellence in Denver
18. September 2024 07:00 ET
|
Employ Inc.
Employ Inc. Opens Center of Excellence in Denver
Pico Partners with Blue Ocean Technologies for After-Hours US Equities Trading Expanding PicoNet’s Capabilities
09. Juli 2024 07:00 ET
|
Pico
Pico clients gain direct access to Blue Ocean Technologies ATS, unlocking expanded capabilities for US equities trading for after-hours trading.
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
22. Mai 2024 11:20 ET
|
Kymera Therapeutics, Inc.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting ...
Upstream Bio Presents Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society International Conference
22. Mai 2024 11:15 ET
|
Upstream Bio, Inc.
Positive results from a Phase 1 dose ranging study of verekitug (UPB-101) in asthma presented at ATS 2024